The Changing Face of Hepatitis B in Greater Glasgow: epidemiological trends 1993-2007

被引:2
作者
Barclay, S. T. [1 ]
Cameron, S. [2 ]
Mills, P. R. [3 ]
Priest, M. [3 ]
Ross, F. [3 ]
Fox, R.
Goulding, C.
Forrest, E. H. [1 ]
Morris, A. J. [1 ]
Neilson, M.
Stanley, A. J.
机构
[1] Glasgow Royal Infirm, Dept Gastroenterol, Glasgow G4 0SF, Lanark, Scotland
[2] Gartnavel Royal Hosp, Brownlee Ctr Infect Dis, Glasgow G12 0XH, Lanark, Scotland
[3] Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland
关键词
ADEFOVIR DIPIVOXIL; VIRUS DNA; LAMIVUDINE; RISK; ENTECAVIR; CIRRHOSIS;
D O I
10.1258/rsmsmj.55.3.4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims Whilst hepatitis B (HBV) is historically uncommon in Scotland, anecdotal experience suggests an increasing prevalence of chronic infection. We sought to establish whether the incidence of chronic HBV is increasing in Greater Glasgow, and whether patients are assessed in secondary care. Methods The regional virus centre database identified HBV surface antigen (HBsAg) positive samples. For adult patients tested in Glasgow between 1993-2007 the first positive test was identified and classified as acute or chronic infection serologically. Clinic referral and attendance data was then obtained. Results 1,672 patients tested HBsAg positive; 1051 with chronic infection, 421 acute and 200 indeterminate. New diagnoses of HBV remained stable over time, however falling numbers of acute cases were mirrored by a rise in chronic cases from 40 to 119 per annum between 2000 and 2007, Of 193 patients diagnosed in 2006 and 2007, 51% were not seen in secondary care due to non referral (43%) or non attendance (8%). Conclusion Chronic HBV trebled in Glasgow between 2000 and 2007. Most patients were not assessed in secondary care. Improved levels of clinic referral and attendance are required to ensure best care for HBV patients in Glasgow.
引用
收藏
页码:4 / 7
页数:4
相关论文
共 22 条
[1]  
CAMERON S, 2008, ANN REP 2007 2008 BL
[2]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[3]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[4]  
*GEN REG OFF SCOT, 2008, SCOTL POP 2007 REG
[5]   Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years [J].
Hadziyannis, Stephanos J. ;
Tassopoulos, Nicolaos C. ;
Heathcote, E. Jenny ;
Chang, Ting-Tsung ;
Kitis, George ;
Rizzetto, Mario ;
Marcellin, Patrick ;
Lik, Seng Gee ;
Goodman, Zachary ;
Ma, Jia ;
Brosgart, Carol L. ;
Eorroto-Esoda, Katyna ;
Arterburn, Sarah ;
Chuck, Steven L. .
GASTROENTEROLOGY, 2006, 131 (06) :1743-1751
[6]  
[Health Protection Agency Health Protection Scotland Public Health Wales CDSC Northern Ireland CRDHB], 2009, SHOOT INF INJ DRUG U
[7]   Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B [J].
Hsu, YS ;
Chien, RN ;
Yeh, CT ;
Sheen, IS ;
Chiou, HY ;
Chu, CM ;
Liaw, YF .
HEPATOLOGY, 2002, 35 (06) :1522-1527
[8]   Predicting cirrhosis risk based on the level of circulating hepatitis B viral load [J].
Iloeje, UH ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Chen, CJ .
GASTROENTEROLOGY, 2006, 130 (03) :678-686
[9]   HBV core sequence: definition of genotype-specific variability and correlation with geographical origin [J].
Jazayeri, M ;
Basuni, AA ;
Sran, N ;
Gish, R ;
Cooksley, G ;
Locarnini, S ;
Carman, WF .
JOURNAL OF VIRAL HEPATITIS, 2004, 11 (06) :488-501
[10]   Chronic Hepatitis B - New Goals, New Treatment [J].
Lai, Ching-Lung ;
Yuen, Man-Fung .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) :2488-2491